Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.
about
Current trends and intricacies in the management of HIV-associated pulmonary tuberculosisA scoping review of cost-effectiveness of screening and treatment for latent tubercolosis infection in migrants from high-incidence countriesThe ongoing challenge of latent tuberculosisEstimating tuberculosis cases and their economic costs averted in the United States over the past two decadesImpacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in TaiwanRevisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis.Cost-Effectiveness of Screening and Treating Foreign-Born Students for Tuberculosis before Entering the United StatesActivism on rifapentine pricing: removing cost barriers to improve the uptake of tuberculosis research innovationsTreatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.A cost-benefit analysis of a proposed overseas refugee latent tuberculosis infection screening and treatment program.Completion Rate and Side-Effect Profile of Three-Month Isoniazid and Rifapentine Treatment for Latent Tuberculosis Infection in an Urban County Jail.A systematic synthesis of direct costs to treat and manage tuberculosis disease applied to California, 2015.Rifapentine for the treatment of latent tuberculosis.The management of infection with Mycobacterium tuberculosis in young children post-2015: an opportunity to close the policy-practice gap.Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.Using Spatial Disease Patterns and Patient-Level Characteristics to Describe Prevalence Elastic Behavior in Treatment for Latent Tuberculosis Infection (LTBI).Treatment for Tuberculosis Infection With 3 Months of Isoniazid and Rifapentine in New York City Health Department Clinics.A comparative effectiveness analysis of treatment for latent tuberculosis infection using multilevel selection models.Editorial Comment: Cost-Effectiveness Analysis for Prioritization of Limited Public Health Resources - Tuberculosis Interventions in Texas.Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model.SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.Cost-effectiveness analysis of interventions for tuberculosis control: DALYs versus QALYs.Tuberculosis in Jails and Prisons: United States, 2002-2013.A shorter treatment regimen for latent tuberculosis infection holds promise for at-risk Canadians.Short-course isoniazid plus rifapentine therapy for latent tuberculosis in Brazil.Incorporation of Social Determinants of Health in the Peer-Reviewed Literature: A Systematic Review of Articles Authored by the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
P2860
Q28069032-CC7B4B27-99CE-4CFE-897D-DA5598C3CEC0Q28081244-DD29CFC3-38D5-4840-86E9-13A5BD5C8780Q28386135-74C0ED49-B834-4C3C-BB39-66D2F15446B9Q28387169-9746F403-09F5-4035-B620-EF452B0BDBB5Q33590461-DA0458E6-7F4C-43F2-92DE-3265BE36864BQ33702764-BEA8FFE9-13F5-43A9-BA58-7AF206FC1925Q35553230-73160901-292C-4FEA-A79F-932F18F64555Q35943990-1CA186A0-AC34-429E-8238-DC934925849EQ36280305-0F792F49-13D5-4617-859E-A81A31A6710BQ36337142-FDAE9951-F9DE-4912-8A31-C0917B3FE2F4Q38426903-3A258A81-4F81-4CBD-92CA-F56AA1AA11D0Q38601841-242642B3-8223-4612-83DF-D5622E6B4EFFQ38933165-E59AC395-6D30-4554-8F85-B5CE3D28F4F3Q39026862-E8607C3D-3910-4B92-B95B-02213483D20AQ39149434-7EB71F14-A8CE-4751-B8A8-9E825177F5B4Q40255221-D7A24519-6E2B-4959-A28F-F2468E1307A7Q40575343-798359F1-AD55-448D-8846-31CD9FA624BEQ41238712-F6B00CFE-105F-475C-BC06-5FF3B41B4262Q41955733-12F2E413-9E97-44E4-9F0D-129C244D79F6Q47640073-15B1097C-479B-4301-98D3-B3E61DF30C2CQ48148161-45EA3E78-0BA6-493C-8647-E1D055F4CCDEQ50682458-E64FD836-6429-4F39-AF62-C3E3DD01245BQ51808682-1A2CF293-AD07-400A-A0ED-5A11B8442FB8Q54207981-1102D4AC-3F27-4022-9DD5-CE2683530526Q54731012-C49AE713-F03A-49E3-9D12-ACF7E39EE31CQ57178901-E65C4994-B077-4F3C-95B7-7FF4E968900B
P2860
Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Cost-effectiveness of a 12-dos ...... nfection in the United States.
@ast
Cost-effectiveness of a 12-dos ...... nfection in the United States.
@en
type
label
Cost-effectiveness of a 12-dos ...... nfection in the United States.
@ast
Cost-effectiveness of a 12-dos ...... nfection in the United States.
@en
prefLabel
Cost-effectiveness of a 12-dos ...... nfection in the United States.
@ast
Cost-effectiveness of a 12-dos ...... nfection in the United States.
@en
P2093
P2860
P356
P1476
Cost-effectiveness of a 12-dos ...... infection in the United States
@en
P2093
A Kerrigan
A S Borisov
D P Holland
D Shepardson
M E Villarino
T R Sterling
P2860
P304
P356
10.5588/IJTLD.13.0423
P577
2013-12-01T00:00:00Z